BHCM
KALV

Brevan Howard Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Brevan Howard Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.42M Buy
125,049
+65,902
+111% +$1.06M 0.02% 480
2025
Q4 		$955K Buy
59,147
+3,269
+6% +$43.3K 0.01% 793
2025
Q3 		$681K Buy
55,878
+42,545
+319% +$588K ﹤0.01% 1119
2025
Q2 		$151K Buy
+13,333
New +$163K ﹤0.01% 1756

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Brevan Howard Capital Management's KALV Position: Q1 2026 in Review

Brevan Howard Capital Management increased its KalVista Pharmaceuticals (KALV) stake by 111% in Q1 2026, buying an estimated $1.06M and bringing the position to 125,049 shares worth $2.42M. The position accounts for 0.02% of the portfolio, ranked #480.

Brevan Howard Capital Management first reported a position in KALV in Q2 2025 and has held it in 4 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Brevan Howard Capital Management held 125,049 shares of KalVista Pharmaceuticals worth $2.42M as of Q1 2026.
  • Brevan Howard Capital Management bought 65,902 KalVista Pharmaceuticals shares in Q1 2026, an estimated $1.06M.
  • KalVista Pharmaceuticals made up 0.02% of Brevan Howard Capital Management's portfolio in Q1 2026, its #480 holding.
  • Brevan Howard Capital Management first reported a position in KalVista Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.